Robot-assisted sutureless partial nephrectomy for the treatment of fifteen bilateral renal masses in a patient with Von Hippel-Lindau syndrome: a case report from a high-volume robotic center.

Journal: CEN case reports
Published Date:

Abstract

Renal cell carcinoma is among major causes of death in patients with Von Hippel-Lindau (VHL) syndrome, and it usually presents with multiple and bilateral lesions that may require multiple renal surgeries. This, in turn, may compromise renal function, resulting in end-stage renal disease. To minimize renal function impairment in these patients, great importance is given to the preservation of functional parenchyma with the use of nephron-sparing techniques. Furthermore, new techniques such as off-clamp surgery, selective suturing or sutureless techniques may improve long-term functional outcomes. We described the case of a 27-year-old male patient with a family history of VHL disease affected by multiple, bilateral renal masses. He received bilateral, metachronous robot-assisted partial nephrectomies (RAPN) for a total of 15 renal lesions. No intra- or post-operative complications occurred, and the patient was discharged on the second postoperative day after both procedures. Serum creatinine after the second RAPN was 0.99 mg/dl (baseline value was 1.11 mg/dl). In patients with VHL syndrome and multiple renal lesions, robot-assisted partial nephrectomy, especially with the use of clampless and sutureless techniques, helps minimizing renal function impairment and should be performed when anatomically and technically feasible.

Authors

  • Maria Peraire Lores
    Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium. mperairelores@gmail.com.
  • Jesús Domínguez
    Department of Population Health Sciences King's College London London UK.
  • Carlo A Bravi
    Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: carloandrea.bravi@gmail.com.
  • Angelo Mottaran
    Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna.
  • Luca Sarchi
    Department of Urology, Ospedale Policlinico e Nuovo Ospedale Civile S. Agostino Estense Modena, University of Modena and Reggio Emilia, Modena, Italy. Electronic address: 279948@studenti.unimore.it.
  • Marco Paciotti
    Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium; Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Adele Piro
    ORSI Academy, Ghent, Belgium.
  • Luigi Nocera
    Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Eleonora Balestrazzi
    Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium; Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Rui Farinha
    Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium.
  • Kim Pauwaert
    Department of Urology, Gent University Hospital, Gent, Belgium.
  • Manoe van Herwaarden
    Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
  • Marie-Hélène Vinckier
    Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium.
  • Pieter De Backer
    ORSI Academy Melle Belgium.
  • Ruben De Groote
    ORSI Academy Melle Belgium.
  • Frederiek D'Hondt
    General Surgery and Urology. OLV Hospital. Belgium.
  • Geert De Naeyer
    General Surgery and Urology. OLV Hospital. Belgium.
  • Alexandre Mottrie
    ORSI Academy Melle Belgium.